PERCEPTIVE ADVISORS

Thesis

Perceptive Advisors is a life sciences investment firm founded in 1999, headquartered in New York City. They focus exclusively on the healthcare and life sciences sectors, with a strong emphasis on biotechnology. Their investment thesis centers on identifying and supporting transformative innovations that have significant therapeutic impact or improve healthcare delivery. They are described as 'superfans of healthcare breakthroughs.' The firm invests across the capital structure, including public and private companies, and supports businesses throughout their growth cycle, from preclinical stages through clinical proof-of-concept. They actively engage with management teams, often taking board seats. Perceptive Advisors invests globally and supports companies from seed and Series A through growth-stage financings, with a dedicated venture capital fund (Perceptive Xontogeny Venture Fund) for earlier-stage biotech startups. They also participate in crossover and pre-IPO rounds. As of June 30, 2026, they managed approximately $11 billion in AUM. For venture capital, their typical check size ranges from $10-50 million, often leading or co-leading Series A financings. For credit opportunities, they aim to invest $20-300 million per investment. The firm employs a team of trained scientists, physicians, and financial analysts to evaluate opportunities.

Related lists

• Seed-stage Healthcare investors
• Series A Healthcare investors
• Series C+ Healthcare investors